Drug Discovery World

JANUARY 15, 2024

For an additional $28 million, Lantheus has obtained an option to exclusively license Perspective’s neuroendocrine tumours treatment Pb212-VMT-⍺-NET, or to co-develop certain early stage therapeutic candidates targeting prostate cancer. of Perspective’s shares for up to $33 million.

Targeted Protein Degradation 147

Targeted Protein Degradation Drugs Small Molecule Licensing 147

Drug Discovery World

DECEMBER 27, 2023

Ng is working on critical challenges in clinical trials, specifically in planning and recruitment, and has been building innovative solutions designed to benefit patients and researchers – with a focus on efficiency, transparency and diversity in clinical development. Listen here. Listen here. This episode is available here.

Targeted Protein Degradation 173

Targeted Protein Degradation Clinical Trials Pharma Companies Drug Development 173

The Pharma Data

SEPTEMBER 25, 2020

. Monte Rosa Therapeutics has raised $96m in Series B financing to support further develop of its pipeline of small-molecule protein degraders. In this process, protein-degrading molecules ‘co-opt’ large cellular proteins (ubiquitin ligases) to breakdown other target proteins, including those that cause cancer.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Clinical Development Disease 40

The Pharma Data

JULY 22, 2021

NYSE: PFE) today announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The companies will equally share worldwide development costs, commercialization expenses, and profits.

Targeted Protein Degradation 52

Targeted Protein Degradation Therapies Clinical Trials Treatment 52

The Pharma Data

DECEMBER 21, 2020

Targeted protein degradation (TPD) is an approach whereby the body’s natural process for degrading proteins is diverted using small molecule drugs to eliminate disease-causing proteins. . TOKYO and CAMBRIDGE, England , Dec. No further financial details are disclosed. ” About Sosei Heptares.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Structure Based Drug Design (SBDD) Drugs 40

Drug Discovery World

OCTOBER 16, 2023

Indeed, this is bolstered by top tier universities like Newcastle University, which specialises in structure-based approaches for drug discovery, developing innovative technologies that support the identification of new medicines, and is well-established in cancer drug discovery.

Drugs 189

Drugs Science Therapies Targeted Protein Degradation 189

Drug Discovery World

MAY 30, 2023

We believe one of the most exciting developments that has high potential to make a significant difference to treating cancer is the novel treatment option to TNBC patients called Immunopheresis. At PhoreMost, we have been particularly excited about the emergence of targeted protein degradation (TPD) as a new therapeutic modality.

Research 130

Research Targeted Protein Degradation Drugs RNA 130